ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1493-1501

  L'Huillier, Arnaud G ^a   Ing Lorenzini, Kuntheavy ^a   Crisinel, Pierre Alex ^a   Rebsamen, Michela C ^a   Fluss, Joel ^a   Korff, Christian M ^a   Barbe, Remy P ^a   Siegrist, Claire Anne ^a   Dayer, Pierre ^a   Posfay Barbe, Klara M ^a   Desmeules, Jules A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

adverse events; anti infective; pediatrics; pharmacogenetics; psychiatric

Indexed keywords

ADENINE; ANTIBIOTIC AGENT; CYTOSINE; GLYCOPROTEIN P; GUANINE; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; PARACETAMOL; THYMINE;

2009 H1N1 INFLUENZA; ABCB1 GENE; ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGITATION; ALLELE; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIPLOTYPE; DNA POLYMORPHISM; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INCIDENCE; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUROPSYCHIATRIC ADVERSE EVENT; NEUROTOXICITY; NEWBORN; NIGHTMARE; PATIENT MONITORING; PEDIATRIC HOSPITAL; PROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SWITZERLAND; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; VOMITING; WILD TYPE;

ADOLESCENT; ANTIVIRAL AGENTS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MENTAL DISORDERS; OSELTAMIVIR; P-GLYCOPROTEIN; PANDEMICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054935564     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.91     Document Type: Article

References (27)

1. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009).
2. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 26(11), 787-801 (2003). (Pubitemid 37056109)
3. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin. Pharmacokinet. 49(11), 741-765 (2010).
4. Abdel-Rahman SM, Newland JG, Kearns GL. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr. Drugs 13(1), 19-31 (2011).
5. Matheson N, Harnden A, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst. Rev. (1), CD002744 (2007).
6. Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334(7606), 1232-1233 (2007). (Pubitemid 46975412)
7. Toovey S, Rayner C, Prinssen E et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 31(12), 1097-1114 (2008).
8. Morimoto K, Nakakariya M, Shirasaka Y et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab. Dispos. 36(1), 6-9 (2008).
9. Ose A, Kusuhara H, Yamatsugu K et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos. 36(2), 427-434 (2008). (Pubitemid 351185757)
10. Jhee SS, Yen M, Ereshefsky L et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob. Agents Chemother. 52(10), 3687-3693 (2008).
11. Clement-Jerdi M, Desmeules J, Dayer P. La glycoprotéine P: un transporteur de médicaments à ne pas négliger. Revue Médicale Suisse 2004(62), 704-709 (2009). (Pubitemid 38468599)
12. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003). (Pubitemid 37372643)
13. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4(4), 397-410 (2003). (Pubitemid 36857176)
14. Ose A, Ito M, Kusuhara H et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxyl ate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab. Dispos. 37(2), 315-321 (2009).
15. Hoffmann G, Funk C, Fowler S et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob. Agents Chemother. 53(11), 4753-4761 (2009).
16. Crisinel PA, Barazzone C, Kaiser L et al. Comparison of clinical presentation of respiratory tract infections in H1N1/09-positive and H1N1/09-negative patients. Eur. J. Pediatr. DOI: 10.1007/s00431-011-1513-7 (2011) (Epub ahead of print).
17. Greenhill LL, Vitiello B, Fisher P et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 43(12), 1488-1496 (2004). (Pubitemid 40468623)
18. Ansermot N, Rebsamen M, Chabert J et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab. Lett. 2(2), 76-82 (2008). (Pubitemid 351983779)
19. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15(2), 97-98 (2005). (Pubitemid 41653949)
20. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004). (Pubitemid 38130115)
21. Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology 20(4), 619-621 (2009).
22. Webster RI, Hazelton B, Suleiman J, Macartney K, Kesson A, Dale RC. Severe encephalopathy with swine origin influenza A H1N1 infection in childhood: case reports. Neurology 74(13), 1077-1078 (2010).
23. Baltagi SA, Shoykhet M, Felmet K, Kochanek PM, Bell MJ. Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic. Pediatr. Crit. Care Med. 11(2), 179-184 (2010).
24. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C T affects mRNA stability. Pharmacogenet. Genomics 15(10), 693-704 (2005). (Pubitemid 41345321)
25. Loeuillet C, Weale M, Deutsch S et al. Promoter polymorphisms and allelic imbalance in ABCB1 expression. Pharmacogenet. Genomics 17(11), 951-959 (2007). (Pubitemid 350293795)
26. Aarnoudse AL, Van Schaik RH, Dieleman J et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther. 80(4), 367-374 (2006). (Pubitemid 44479754)
27. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003). (Pubitemid 37034590)